SCI Pharmtech（4119）株式概要SCI Pharmtech, Inc.は、その子会社とともに、イタリア、米国、日本、ドイツ、台湾、スイス、中国、および世界各国において、医薬品原薬、中間体、特殊化学品の研究開発、製造、販売を行っている。 詳細4119 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績2/6財務の健全性5/6配当金1/6リスク分析1.82%の配当は、利益やフリーキャッシュフローによって十分にカバーされていない 利益率(7%)は昨年より低い(33.2%) すべてのリスクチェックを見る4119 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueNT$Current PriceNT$41.3011.6% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture03b2016201920222025202620282031Revenue NT$1.6bEarnings NT$110.9mAdvancedSet Fair ValueView all narrativesSCI Pharmtech, Inc. 競合他社CenraSymbol: TWSE:3716Market cap: NT$5.1bSinphar PharmaceuticalLtdSymbol: TWSE:1734Market cap: NT$5.8bPanion & Bf BiotechSymbol: TWSE:1760Market cap: NT$5.2bSavior LifetecSymbol: TPEX:4167Market cap: NT$5.9b価格と性能株価の高値、安値、推移の概要SCI Pharmtech過去の株価現在の株価NT$41.3052週高値NT$70.9052週安値NT$40.05ベータ0.0961ヶ月の変化-14.40%3ヶ月変化-23.09%1年変化-41.25%3年間の変化-59.60%5年間の変化-34.71%IPOからの変化108.24%最新ニュースReported Earnings • May 09First quarter 2026 earnings released: EPS: NT$0.17 (vs NT$0.27 in 1Q 2025)First quarter 2026 results: EPS: NT$0.17 (down from NT$0.27 in 1Q 2025). Revenue: NT$375.8m (up 4.3% from 1Q 2025). Net income: NT$20.1m (down 37% from 1Q 2025). Profit margin: 5.4% (down from 8.8% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 25% per year.お知らせ • Mar 06SCI Pharmtech, Inc., Annual General Meeting, May 22, 2026SCI Pharmtech, Inc., Annual General Meeting, May 22, 2026. Location: no,61 ln.309, hai hu n. rd., lujhu district, taoyuan city TaiwanReported Earnings • Mar 06Full year 2025 earnings released: EPS: NT$0.90 (vs NT$4.47 in FY 2024)Full year 2025 results: EPS: NT$0.90 (down from NT$4.47 in FY 2024). Revenue: NT$1.34b (down 12% from FY 2024). Net income: NT$107.4m (down 80% from FY 2024). Profit margin: 8.0% (down from 35% in FY 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.Reported Earnings • Nov 08Third quarter 2025 earnings released: EPS: NT$0.12 (vs NT$3.19 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.12 (down from NT$3.19 in 3Q 2024). Revenue: NT$256.4m (down 39% from 3Q 2024). Net income: NT$14.0m (down 96% from 3Q 2024). Profit margin: 5.5% (down from 91% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 09Second quarter 2025 earnings released: EPS: NT$0.19 (vs NT$0.52 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.19 (down from NT$0.52 in 2Q 2024). Revenue: NT$371.5m (down 5.4% from 2Q 2024). Net income: NT$22.8m (down 63% from 2Q 2024). Profit margin: 6.1% (down from 16% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Upcoming Dividend • Jun 24Upcoming dividend of NT$1.50 per shareEligible shareholders must have bought the stock before 01 July 2025. Payment date: 05 August 2025. Payout ratio is a comfortable 34% but the company is not cash flow positive. Trailing yield: 2.3%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (2.6%).最新情報をもっと見るRecent updatesReported Earnings • May 09First quarter 2026 earnings released: EPS: NT$0.17 (vs NT$0.27 in 1Q 2025)First quarter 2026 results: EPS: NT$0.17 (down from NT$0.27 in 1Q 2025). Revenue: NT$375.8m (up 4.3% from 1Q 2025). Net income: NT$20.1m (down 37% from 1Q 2025). Profit margin: 5.4% (down from 8.8% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 25% per year.お知らせ • Mar 06SCI Pharmtech, Inc., Annual General Meeting, May 22, 2026SCI Pharmtech, Inc., Annual General Meeting, May 22, 2026. Location: no,61 ln.309, hai hu n. rd., lujhu district, taoyuan city TaiwanReported Earnings • Mar 06Full year 2025 earnings released: EPS: NT$0.90 (vs NT$4.47 in FY 2024)Full year 2025 results: EPS: NT$0.90 (down from NT$4.47 in FY 2024). Revenue: NT$1.34b (down 12% from FY 2024). Net income: NT$107.4m (down 80% from FY 2024). Profit margin: 8.0% (down from 35% in FY 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.Reported Earnings • Nov 08Third quarter 2025 earnings released: EPS: NT$0.12 (vs NT$3.19 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.12 (down from NT$3.19 in 3Q 2024). Revenue: NT$256.4m (down 39% from 3Q 2024). Net income: NT$14.0m (down 96% from 3Q 2024). Profit margin: 5.5% (down from 91% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 09Second quarter 2025 earnings released: EPS: NT$0.19 (vs NT$0.52 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.19 (down from NT$0.52 in 2Q 2024). Revenue: NT$371.5m (down 5.4% from 2Q 2024). Net income: NT$22.8m (down 63% from 2Q 2024). Profit margin: 6.1% (down from 16% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Upcoming Dividend • Jun 24Upcoming dividend of NT$1.50 per shareEligible shareholders must have bought the stock before 01 July 2025. Payment date: 05 August 2025. Payout ratio is a comfortable 34% but the company is not cash flow positive. Trailing yield: 2.3%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (2.6%).Declared Dividend • Jun 07Dividend increased to NT$1.50Dividend of NT$1.50 is 20% higher than last year. Ex-date: 1st July 2025 Payment date: 5th August 2025 Dividend yield will be 2.2%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 62% to shift the payout ratio to a potentially unsustainable range, which is more than the 5.3% EPS decline seen over the last 5 years.Reported Earnings • May 10First quarter 2025 earnings released: EPS: NT$0.27 (vs NT$0.37 in 1Q 2024)First quarter 2025 results: EPS: NT$0.27 (down from NT$0.37 in 1Q 2024). Revenue: NT$360.3m (up 16% from 1Q 2024). Net income: NT$31.7m (down 29% from 1Q 2024). Profit margin: 8.8% (down from 14% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • May 02SCI Pharmtech, Inc. to Report Q1, 2025 Results on May 09, 2025SCI Pharmtech, Inc. announced that they will report Q1, 2025 results on May 09, 2025Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$65.00, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 11x in the Pharmaceuticals industry in Taiwan. Total loss to shareholders of 9.9% over the past three years.New Risk • Mar 26New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 205% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.2% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results.New Risk • Mar 25New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.8% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.2% per year over the past 5 years. Minor Risk Paying a dividend despite having no free cash flows.お知らせ • Mar 13SCI Pharmtech, Inc., Annual General Meeting, May 26, 2025SCI Pharmtech, Inc., Annual General Meeting, May 26, 2025, at 09:00 Taipei Standard Time. Location: no,61 ln.309, hai hu n. rd., lujhu district, taoyuan city TaiwanReported Earnings • Mar 12Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: NT$4.47 (up from NT$2.70 in FY 2023). Revenue: NT$1.52b (up 27% from FY 2023). Net income: NT$534.7m (up 81% from FY 2023). Profit margin: 35% (up from 25% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.5%. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 12Sci Pharmtech, Inc. Declares Dividend for Period from January 01, 2024 to December 31, 2024SCI Pharmtech, Inc. declared dividend of TWD 1.5 per share for the period from January 01, 2024 to December 31, 2024. Total amount of cash distributed to shareholders TWD 179,262,951.お知らせ • Mar 01SCI Pharmtech, Inc. to Report Fiscal Year 2024 Results on Mar 10, 2025SCI Pharmtech, Inc. announced that they will report fiscal year 2024 results on Mar 10, 2025お知らせ • Jan 10Sci Pharmtech, Inc. Announces Cash Dividend PaymentSCI Pharmtech, Inc. announced cash dividend of TWD 543,772.分析記事 • Nov 17Shareholders Shouldn’t Be Too Comfortable With SCI Pharmtech's (TWSE:4119) Strong EarningsWe didn't see SCI Pharmtech, Inc.'s ( TWSE:4119 ) stock surge when it reported robust earnings recently. We decided to...Reported Earnings • Nov 11Third quarter 2024 earnings released: EPS: NT$3.19 (vs NT$0.33 in 3Q 2023)Third quarter 2024 results: EPS: NT$3.19 (up from NT$0.33 in 3Q 2023). Revenue: NT$419.3m (up 63% from 3Q 2023). Net income: NT$381.1m (up NT$345.8m from 3Q 2023). Profit margin: 91% (up from 14% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.New Risk • Aug 17New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 11% Last year net profit margin: 33% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (11% net profit margin). Shareholders have been diluted in the past year (11% increase in shares outstanding).Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$0.52 (vs NT$1.86 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.52 (down from NT$1.86 in 2Q 2023). Revenue: NT$392.7m (up 25% from 2Q 2023). Net income: NT$62.2m (down 69% from 2Q 2023). Profit margin: 16% (down from 64% in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 02SCI Pharmtech, Inc. to Report Q2, 2024 Results on Aug 09, 2024SCI Pharmtech, Inc. announced that they will report Q2, 2024 results on Aug 09, 2024Upcoming Dividend • Jun 24Upcoming dividend of NT$1.25 per shareEligible shareholders must have bought the stock before 01 July 2024. Payment date: 05 August 2024. Payout ratio is a comfortable 51% but the company is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of Taiwanese dividend payers (4.2%). Lower than average of industry peers (2.0%).Reported Earnings • May 20First quarter 2024 earnings released: EPS: NT$0.37 (vs NT$0.59 in 1Q 2023)First quarter 2024 results: EPS: NT$0.37 (down from NT$0.59 in 1Q 2023). Revenue: NT$309.9m (down 9.3% from 1Q 2023). Net income: NT$44.5m (down 30% from 1Q 2023). Profit margin: 14% (down from 19% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.お知らせ • May 10SCI Pharmtech, Inc. Announces Board ChangesSCI Pharmtech, Inc. announced the change of juristic-person representative director. Name of the previous position holder: Aurora Chen; Resume of the previous position holder: Director of Yushan Pharmaceuticals Inc.; Name of the new position holder: Hsu, Chin-Hsin; Resume of the new position holder: Attorney General of Mercuries & Associates Holding Ltd. Reason for the change: Corporate Director Reassignment as Representative. Effective date of the new appointment is May 10, 2024.お知らせ • May 02SCI Pharmtech, Inc. to Report Q1, 2024 Results on May 09, 2024SCI Pharmtech, Inc. announced that they will report Q1, 2024 results on May 09, 2024分析記事 • Mar 27We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish EarningsShareholders didn't appear too concerned by SCI Pharmtech, Inc.'s ( TWSE:4119 ) weak earnings. We did some analysis and...Reported Earnings • Mar 21Full year 2023 earnings released: EPS: NT$2.70 (vs NT$2.88 in FY 2022)Full year 2023 results: EPS: NT$2.70 (down from NT$2.88 in FY 2022). Revenue: NT$1.20b (up 34% from FY 2022). Net income: NT$294.7m (down 4.6% from FY 2022). Profit margin: 25% (down from 34% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 14SCI Pharmtech, Inc., Annual General Meeting, May 30, 2024SCI Pharmtech, Inc., Annual General Meeting, May 30, 2024.Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: NT$0.33 (vs NT$0.45 in 3Q 2022)Third quarter 2023 results: EPS: NT$0.33 (down from NT$0.45 in 3Q 2022). Revenue: NT$257.8m (down 15% from 3Q 2022). Net income: NT$35.4m (down 27% from 3Q 2022). Profit margin: 14% (down from 16% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.New Risk • Nov 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 21% per year over the past 5 years. High level of non-cash earnings (29% accrual ratio). Minor Risk Shareholders have been diluted in the past year (11% increase in shares outstanding).お知らせ • Sep 27SCI Pharmtech, Inc. announced that it expects to receive TWD 120 million in fundingSCI Pharmtech, Inc. announced a private placement to issue up to 12,000,000 common shares at an issue price of TWD 10 per share for the aggregate gross proceeds of TWD 120,000,000 on September 25, 2023. The transaction has been approved by the board of directors of the company.Reported Earnings • Aug 13Second quarter 2023 earnings released: EPS: NT$1.86 (vs NT$1.31 in 2Q 2022)Second quarter 2023 results: EPS: NT$1.86 (up from NT$1.31 in 2Q 2022). Revenue: NT$313.1m (up 73% from 2Q 2022). Net income: NT$199.5m (up 42% from 2Q 2022). Profit margin: 64% (down from 77% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Upcoming Dividend • Jul 20Upcoming dividend of NT$0.25 per share at 0.2% yieldEligible shareholders must have bought the stock before 27 July 2023. Payment date: 01 September 2023. Trailing yield: 0.2%. Lower than top quartile of Taiwanese dividend payers (5.5%). Lower than average of industry peers (1.4%).お知らせ • Jul 06SCI Pharmtech, Inc. Announces Cash Dividend, Payable on September 1, 2023SCI Pharmtech, Inc. announced a cash dividend of TWD 23,845,593; TWD 0.25/per share. Ex-rights (ex-dividend) trading date is July 27, 2023. Ex-rights (ex-dividend) record date is August 2, 2023. The Payment date of cash dividend distribution is September 1, 2023.Reported Earnings • Mar 24Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: NT$3.24 (up from NT$0.58 in FY 2021). Revenue: NT$899.7m (up 4.1% from FY 2021). Net income: NT$308.8m (up 454% from FY 2021). Profit margin: 34% (up from 6.4% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 49% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.Price Target Changed • Feb 01Price target increased by 24% to NT$104Up from NT$84.00, the current price target is an average from 2 analysts. New target price is 6.8% above last closing price of NT$97.40. Stock is up 18% over the past year. The company is forecast to post earnings per share of NT$2.70 for next year compared to NT$0.58 last year.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Wang Vincent was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Buying Opportunity • Nov 09Now 21% undervaluedOver the last 90 days, the stock is up 8.0%. The fair value is estimated to be NT$112, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 209% in 2 years. Earnings is forecast to grow by 243% in the next 2 years.Major Estimate Revision • Aug 30Consensus revenue estimates fall by 25%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from NT$1.11b to NT$834.0m. EPS estimate fell from NT$4.90 to NT$2.53 per share. Net income forecast to grow 170% next year vs 49% growth forecast for Pharmaceuticals industry in Taiwan. Consensus price target up from NT$84.00 to NT$86.00. Share price rose 2.2% to NT$88.20 over the past week.Reported Earnings • Aug 15Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: EPS: NT$1.47 (up from NT$0.039 in 2Q 2021). Revenue: NT$181.4m (up 2.7% from 2Q 2021). Net income: NT$140.3m (up NT$136.6m from 2Q 2021). Profit margin: 77% (up from 2.1% in 2Q 2021). The increase in margin was primarily driven by lower expenses. Revenue missed analyst estimates by 24%. Earnings per share (EPS) also missed analyst estimates by 63%. Over the next year, revenue is forecast to grow 134%, compared to a 27% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance.お知らせ • Jun 30SCI Pharmtech, Inc. Announces Appointment of General Manager of the Board of DirectorsSCI Pharmtech, Inc. announced appointment of general manager of the Board of Directors. Name of the previous position holder: Mr. Weichyun Wong. Resume of the previous position holder: general manager of SCI Pharmtech, Inc. 5.Name of the new position holder: Mr. Wen-Chih Chou. Resume of the new position holder: Plant Manager of SCI Pharmtech, Inc. Effective date of the new appointment is June 29, 2022.Reported Earnings • May 09First quarter 2022 earnings: EPS exceeds analyst expectationsFirst quarter 2022 results: EPS: NT$0.43 (down from NT$0.44 in 1Q 2021). Revenue: NT$188.0m (down 42% from 1Q 2021). Net income: NT$41.2m (down 1.2% from 1Q 2021). Profit margin: 22% (up from 13% in 1Q 2021). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Over the next year, revenue is forecast to grow 94%, compared to a 21% growth forecast for the industry in Taiwan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.Price Target Changed • Apr 27Price target increased to NT$84.00Up from NT$66.94, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$82.00. Stock is up 7.9% over the past year. The company is forecast to post earnings per share of NT$4.90 for next year compared to NT$0.58 last year.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Jay Chen was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 07Third quarter 2021 earnings released: EPS NT$0.31 (vs NT$1.98 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$228.3m (down 66% from 3Q 2020). Net income: NT$29.9m (down 84% from 3Q 2020). Profit margin: 13% (down from 28% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.Upcoming Dividend • Aug 16Upcoming dividend of NT$0.50 per shareEligible shareholders must have bought the stock before 23 August 2021. Payment date: 28 September 2021. Trailing yield: 0.5%. Lower than top quartile of Taiwanese dividend payers (5.2%). Lower than average of industry peers (2.3%).Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS NT$0.05 (vs NT$3.04 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$176.6m (down 76% from 2Q 2020). Net income: NT$3.75m (down 98% from 2Q 2020). Profit margin: 2.1% (down from 33% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Reported Earnings • May 08First quarter 2021 earnings released: EPS NT$0.52 (vs NT$2.62 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: NT$323.6m (down 59% from 1Q 2020). Net income: NT$41.7m (down 80% from 1Q 2020). Profit margin: 13% (down from 27% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 13% per year.分析記事 • Apr 07Analysts Just Shipped A Captivating Upgrade To Their SCI Pharmtech, Inc. (TPE:4119) EstimatesSCI Pharmtech, Inc. ( TPE:4119 ) shareholders will have a reason to smile today, with the analysts making substantial...Major Estimate Revision • Apr 07Consensus revenue estimates increase to NT$742.0mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from NT$609.0m to NT$742.0m. EPS estimate increased from NT$0.56 to NT$1.18 per share. Net income forecast to shrink 74% next year vs 10% growth forecast for Pharmaceuticals industry in Taiwan . Consensus price target up from NT$80.33 to NT$89.33. Share price was steady at NT$94.10 over the past week.分析記事 • Mar 30There May Be Reason For Hope In SCI Pharmtech's (TPE:4119) Disappointing EarningsThe market for SCI Pharmtech, Inc.'s ( TPE:4119 ) shares didn't move much after it posted weak earnings recently. Our...Reported Earnings • Mar 25Full year 2020 earnings released: EPS NT$4.53 (vs NT$7.19 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: NT$2.69b (up 14% from FY 2019). Net income: NT$360.1m (down 37% from FY 2019). Profit margin: 13% (down from 24% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.分析記事 • Mar 08SCI Pharmtech, Inc. (TPE:4119) Is Yielding 6.3% - But Is It A Buy?Today we'll take a closer look at SCI Pharmtech, Inc. ( TPE:4119 ) from a dividend investor's perspective. Owning a...分析記事 • Jan 25SCI Pharmtech (TPE:4119) Shareholders Booked A 54% Gain In The Last Three YearsSCI Pharmtech, Inc. ( TPE:4119 ) shareholders might be concerned after seeing the share price drop 21% in the last...Valuation Update With 7 Day Price Move • Jan 13Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$98.00, the stock is trading at a trailing P/E ratio of 10.7x, up from the previous P/E ratio of 9.1x. This compares to an average P/E of 18x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders over the past three years are 79%.分析記事 • Dec 30Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's EstimatesMarket forces rained on the parade of SCI Pharmtech, Inc. ( TPE:4119 ) shareholders today, when the analysts downgraded...Major Estimate Revision • Dec 30Analysts update estimatesThe 2020 consensus revenue estimate increased from NT$2.73b to NT$2.78b. Earnings per share (EPS) estimate was lowered from NT$9.58 to NT$5.75 for the same period. Net income is expected to shrink by 58% next year compared to 48% growth forecast for the Pharmaceuticals industry in Taiwan . The consensus price target was lowered from NT$109 to NT$85.67. Share price is down by 8.7% to NT$83.00 over the past week.分析記事 • Dec 29Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?SCI Pharmtech (TPE:4119) has had a rough month with its share price down 36%. But if you pay close attention, you might...Price Target Changed • Dec 22Price target lowered to NT$109Down from NT$131, the current price target is an average from 4 analysts. The new target price is 8.3% above the current share price of NT$101. As of last close, the stock is down 5.6% over the past year.Valuation Update With 7 Day Price Move • Dec 22Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to NT$101, the stock is trading at a trailing P/E ratio of 11x, down from the previous P/E ratio of 13.6x. This compares to an average P/E of 19x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders over the past three years are 97%.Is New 90 Day High Low • Dec 21New 90-day low: NT$112The company is down 8.0% from its price of NT$122 on 22 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is NT$139 per share.分析記事 • Dec 08Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?Is SCI Pharmtech, Inc. ( TPE:4119 ) a good dividend stock? How can we tell? Dividend paying companies with growing...分析記事 • Nov 17A Look At The Intrinsic Value Of SCI Pharmtech, Inc. (TPE:4119)In this article we are going to estimate the intrinsic value of SCI Pharmtech, Inc. (TPE:4119) by taking the expected...Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS NT$2.38The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$678.8m (up 8.1% from 3Q 2019). Net income: NT$188.9m (up 18% from 3Q 2019). Profit margin: 28% (up from 26% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.Analyst Estimate Surprise Post Earnings • Nov 15Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 0.05%. Earnings per share (EPS) missed analyst estimates by 2.1%. Over the next year, revenue is forecast to stay flat compared to a 79% growth forecast for the Pharmaceuticals industry in Taiwan.Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS NT$2.38The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$678.8m (up 8.1% from 3Q 2019). Net income: NT$188.9m (up 18% from 3Q 2019). Profit margin: 28% (up from 26% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth.Analyst Estimate Surprise Post Earnings • Nov 07Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 0.05%. Earnings per share (EPS) missed analyst estimates by 2.1%. Over the next year, revenue is forecast to stay flat compared to a 73% growth forecast for the Pharmaceuticals industry in Taiwan.株主還元4119TW PharmaceuticalsTW 市場7D-0.7%3.4%6.6%1Y-41.3%-5.0%102.0%株主還元を見る業界別リターン: 4119過去 1 年間で-5 % の収益を上げたTW Pharmaceuticals業界を下回りました。リターン対市場: 4119は、過去 1 年間で102 % のリターンを上げたTW市場を下回りました。価格変動Is 4119's price volatile compared to industry and market?4119 volatility4119 Average Weekly Movement4.0%Pharmaceuticals Industry Average Movement5.4%Market Average Movement6.2%10% most volatile stocks in TW Market12.3%10% least volatile stocks in TW Market2.5%安定した株価: 4119 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 4119の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1987n/aWen-Chih Chouwww.sci-pharmtech.com.twSCI Pharmtech, Inc.は、その子会社とともに、イタリア、米国、日本、ドイツ、台湾、スイス、中国、および海外において、医薬品原薬、中間体、特殊化学品の研究開発、製造、販売を行っている。同社は、アデニン、アルチカイン塩酸塩、アトモキセチン塩酸塩、ビソプロロールヘミフマル酸塩、ブリンゾラミド、ブプレノルフィンおよびブプレノルフィン塩酸塩、カンナビドール、ジバルプロエクスナトリウムなどの原薬を提供している、デュロキセチン塩酸塩、ヒドロキシクロロキン硫酸塩、ロキソプロフェンナトリウム、メチルフェニデート塩酸塩、ペントバルビタールナトリウム、ピモベンダン、プロブコール、プロパフェノンHCI、バルプロ酸ナトリウム、チオペンタール、バルプロ酸；ベンセラジド、CBN、CBDを開発。また、マロン酸ジエチルイソブチル、ベンズヒドリルアミン、1-ベンズヒドリルアゼチジン-3-オール、アゼチジン-3-オール塩酸水素塩、1-(2-ヒドロキシフェニル)-3-フェニルプロパン-1-オン、リタリン酸、d-リタリン酸塩酸塩などの中間体も提供している、ピロガロールアルデヒド、メンタジエノール、5-ペンチルベンゼン-1,3-ジオールオリベトール、2,4-ジヒドロキシ-6-ペンチル安息香酸メチル、2,4-ジヒドロキシ-6-ペンチル安息香酸エチルオリベトレート、ジバリノール、リスデキサムフェタミン中間体、UDP-GIcNAz、UDP-GaINAz。さらに、同社はカスタマイズされた生産サービスも提供している。同社は1987年に設立され、台湾の桃園市に拠点を置く。もっと見るSCI Pharmtech, Inc. 基礎のまとめSCI Pharmtech の収益と売上を時価総額と比較するとどうか。4119 基礎統計学時価総額NT$4.94b収益（TTM）NT$95.75m売上高(TTM)NT$1.36b51.5xPER（株価収益率3.6xP/Sレシオ4119 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計4119 損益計算書（TTM）収益NT$1.36b売上原価NT$1.01b売上総利益NT$354.19mその他の費用NT$258.44m収益NT$95.75m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）0.80グロス・マージン26.06%純利益率7.04%有利子負債／自己資本比率12.8%4119 の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.8%現在の配当利回り94%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 07:14終値2026/05/25 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SCI Pharmtech, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Yu-Ying YangKGI Securities Co. Ltd.Xiaowei HuangMasterlink Securities Investment AdvisoryYijun ChenSinoPac Securities Investment Service1 その他のアナリストを表示
Reported Earnings • May 09First quarter 2026 earnings released: EPS: NT$0.17 (vs NT$0.27 in 1Q 2025)First quarter 2026 results: EPS: NT$0.17 (down from NT$0.27 in 1Q 2025). Revenue: NT$375.8m (up 4.3% from 1Q 2025). Net income: NT$20.1m (down 37% from 1Q 2025). Profit margin: 5.4% (down from 8.8% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 25% per year.
お知らせ • Mar 06SCI Pharmtech, Inc., Annual General Meeting, May 22, 2026SCI Pharmtech, Inc., Annual General Meeting, May 22, 2026. Location: no,61 ln.309, hai hu n. rd., lujhu district, taoyuan city Taiwan
Reported Earnings • Mar 06Full year 2025 earnings released: EPS: NT$0.90 (vs NT$4.47 in FY 2024)Full year 2025 results: EPS: NT$0.90 (down from NT$4.47 in FY 2024). Revenue: NT$1.34b (down 12% from FY 2024). Net income: NT$107.4m (down 80% from FY 2024). Profit margin: 8.0% (down from 35% in FY 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Nov 08Third quarter 2025 earnings released: EPS: NT$0.12 (vs NT$3.19 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.12 (down from NT$3.19 in 3Q 2024). Revenue: NT$256.4m (down 39% from 3Q 2024). Net income: NT$14.0m (down 96% from 3Q 2024). Profit margin: 5.5% (down from 91% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 09Second quarter 2025 earnings released: EPS: NT$0.19 (vs NT$0.52 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.19 (down from NT$0.52 in 2Q 2024). Revenue: NT$371.5m (down 5.4% from 2Q 2024). Net income: NT$22.8m (down 63% from 2Q 2024). Profit margin: 6.1% (down from 16% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Jun 24Upcoming dividend of NT$1.50 per shareEligible shareholders must have bought the stock before 01 July 2025. Payment date: 05 August 2025. Payout ratio is a comfortable 34% but the company is not cash flow positive. Trailing yield: 2.3%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (2.6%).
Reported Earnings • May 09First quarter 2026 earnings released: EPS: NT$0.17 (vs NT$0.27 in 1Q 2025)First quarter 2026 results: EPS: NT$0.17 (down from NT$0.27 in 1Q 2025). Revenue: NT$375.8m (up 4.3% from 1Q 2025). Net income: NT$20.1m (down 37% from 1Q 2025). Profit margin: 5.4% (down from 8.8% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 25% per year.
お知らせ • Mar 06SCI Pharmtech, Inc., Annual General Meeting, May 22, 2026SCI Pharmtech, Inc., Annual General Meeting, May 22, 2026. Location: no,61 ln.309, hai hu n. rd., lujhu district, taoyuan city Taiwan
Reported Earnings • Mar 06Full year 2025 earnings released: EPS: NT$0.90 (vs NT$4.47 in FY 2024)Full year 2025 results: EPS: NT$0.90 (down from NT$4.47 in FY 2024). Revenue: NT$1.34b (down 12% from FY 2024). Net income: NT$107.4m (down 80% from FY 2024). Profit margin: 8.0% (down from 35% in FY 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Nov 08Third quarter 2025 earnings released: EPS: NT$0.12 (vs NT$3.19 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.12 (down from NT$3.19 in 3Q 2024). Revenue: NT$256.4m (down 39% from 3Q 2024). Net income: NT$14.0m (down 96% from 3Q 2024). Profit margin: 5.5% (down from 91% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 09Second quarter 2025 earnings released: EPS: NT$0.19 (vs NT$0.52 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.19 (down from NT$0.52 in 2Q 2024). Revenue: NT$371.5m (down 5.4% from 2Q 2024). Net income: NT$22.8m (down 63% from 2Q 2024). Profit margin: 6.1% (down from 16% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Jun 24Upcoming dividend of NT$1.50 per shareEligible shareholders must have bought the stock before 01 July 2025. Payment date: 05 August 2025. Payout ratio is a comfortable 34% but the company is not cash flow positive. Trailing yield: 2.3%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (2.6%).
Declared Dividend • Jun 07Dividend increased to NT$1.50Dividend of NT$1.50 is 20% higher than last year. Ex-date: 1st July 2025 Payment date: 5th August 2025 Dividend yield will be 2.2%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 62% to shift the payout ratio to a potentially unsustainable range, which is more than the 5.3% EPS decline seen over the last 5 years.
Reported Earnings • May 10First quarter 2025 earnings released: EPS: NT$0.27 (vs NT$0.37 in 1Q 2024)First quarter 2025 results: EPS: NT$0.27 (down from NT$0.37 in 1Q 2024). Revenue: NT$360.3m (up 16% from 1Q 2024). Net income: NT$31.7m (down 29% from 1Q 2024). Profit margin: 8.8% (down from 14% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • May 02SCI Pharmtech, Inc. to Report Q1, 2025 Results on May 09, 2025SCI Pharmtech, Inc. announced that they will report Q1, 2025 results on May 09, 2025
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$65.00, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 11x in the Pharmaceuticals industry in Taiwan. Total loss to shareholders of 9.9% over the past three years.
New Risk • Mar 26New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 205% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.2% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results.
New Risk • Mar 25New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.8% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.2% per year over the past 5 years. Minor Risk Paying a dividend despite having no free cash flows.
お知らせ • Mar 13SCI Pharmtech, Inc., Annual General Meeting, May 26, 2025SCI Pharmtech, Inc., Annual General Meeting, May 26, 2025, at 09:00 Taipei Standard Time. Location: no,61 ln.309, hai hu n. rd., lujhu district, taoyuan city Taiwan
Reported Earnings • Mar 12Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: NT$4.47 (up from NT$2.70 in FY 2023). Revenue: NT$1.52b (up 27% from FY 2023). Net income: NT$534.7m (up 81% from FY 2023). Profit margin: 35% (up from 25% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.5%. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 12Sci Pharmtech, Inc. Declares Dividend for Period from January 01, 2024 to December 31, 2024SCI Pharmtech, Inc. declared dividend of TWD 1.5 per share for the period from January 01, 2024 to December 31, 2024. Total amount of cash distributed to shareholders TWD 179,262,951.
お知らせ • Mar 01SCI Pharmtech, Inc. to Report Fiscal Year 2024 Results on Mar 10, 2025SCI Pharmtech, Inc. announced that they will report fiscal year 2024 results on Mar 10, 2025
お知らせ • Jan 10Sci Pharmtech, Inc. Announces Cash Dividend PaymentSCI Pharmtech, Inc. announced cash dividend of TWD 543,772.
分析記事 • Nov 17Shareholders Shouldn’t Be Too Comfortable With SCI Pharmtech's (TWSE:4119) Strong EarningsWe didn't see SCI Pharmtech, Inc.'s ( TWSE:4119 ) stock surge when it reported robust earnings recently. We decided to...
Reported Earnings • Nov 11Third quarter 2024 earnings released: EPS: NT$3.19 (vs NT$0.33 in 3Q 2023)Third quarter 2024 results: EPS: NT$3.19 (up from NT$0.33 in 3Q 2023). Revenue: NT$419.3m (up 63% from 3Q 2023). Net income: NT$381.1m (up NT$345.8m from 3Q 2023). Profit margin: 91% (up from 14% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
New Risk • Aug 17New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 11% Last year net profit margin: 33% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (11% net profit margin). Shareholders have been diluted in the past year (11% increase in shares outstanding).
Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$0.52 (vs NT$1.86 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.52 (down from NT$1.86 in 2Q 2023). Revenue: NT$392.7m (up 25% from 2Q 2023). Net income: NT$62.2m (down 69% from 2Q 2023). Profit margin: 16% (down from 64% in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 02SCI Pharmtech, Inc. to Report Q2, 2024 Results on Aug 09, 2024SCI Pharmtech, Inc. announced that they will report Q2, 2024 results on Aug 09, 2024
Upcoming Dividend • Jun 24Upcoming dividend of NT$1.25 per shareEligible shareholders must have bought the stock before 01 July 2024. Payment date: 05 August 2024. Payout ratio is a comfortable 51% but the company is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of Taiwanese dividend payers (4.2%). Lower than average of industry peers (2.0%).
Reported Earnings • May 20First quarter 2024 earnings released: EPS: NT$0.37 (vs NT$0.59 in 1Q 2023)First quarter 2024 results: EPS: NT$0.37 (down from NT$0.59 in 1Q 2023). Revenue: NT$309.9m (down 9.3% from 1Q 2023). Net income: NT$44.5m (down 30% from 1Q 2023). Profit margin: 14% (down from 19% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
お知らせ • May 10SCI Pharmtech, Inc. Announces Board ChangesSCI Pharmtech, Inc. announced the change of juristic-person representative director. Name of the previous position holder: Aurora Chen; Resume of the previous position holder: Director of Yushan Pharmaceuticals Inc.; Name of the new position holder: Hsu, Chin-Hsin; Resume of the new position holder: Attorney General of Mercuries & Associates Holding Ltd. Reason for the change: Corporate Director Reassignment as Representative. Effective date of the new appointment is May 10, 2024.
お知らせ • May 02SCI Pharmtech, Inc. to Report Q1, 2024 Results on May 09, 2024SCI Pharmtech, Inc. announced that they will report Q1, 2024 results on May 09, 2024
分析記事 • Mar 27We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish EarningsShareholders didn't appear too concerned by SCI Pharmtech, Inc.'s ( TWSE:4119 ) weak earnings. We did some analysis and...
Reported Earnings • Mar 21Full year 2023 earnings released: EPS: NT$2.70 (vs NT$2.88 in FY 2022)Full year 2023 results: EPS: NT$2.70 (down from NT$2.88 in FY 2022). Revenue: NT$1.20b (up 34% from FY 2022). Net income: NT$294.7m (down 4.6% from FY 2022). Profit margin: 25% (down from 34% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 14SCI Pharmtech, Inc., Annual General Meeting, May 30, 2024SCI Pharmtech, Inc., Annual General Meeting, May 30, 2024.
Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: NT$0.33 (vs NT$0.45 in 3Q 2022)Third quarter 2023 results: EPS: NT$0.33 (down from NT$0.45 in 3Q 2022). Revenue: NT$257.8m (down 15% from 3Q 2022). Net income: NT$35.4m (down 27% from 3Q 2022). Profit margin: 14% (down from 16% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
New Risk • Nov 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 21% per year over the past 5 years. High level of non-cash earnings (29% accrual ratio). Minor Risk Shareholders have been diluted in the past year (11% increase in shares outstanding).
お知らせ • Sep 27SCI Pharmtech, Inc. announced that it expects to receive TWD 120 million in fundingSCI Pharmtech, Inc. announced a private placement to issue up to 12,000,000 common shares at an issue price of TWD 10 per share for the aggregate gross proceeds of TWD 120,000,000 on September 25, 2023. The transaction has been approved by the board of directors of the company.
Reported Earnings • Aug 13Second quarter 2023 earnings released: EPS: NT$1.86 (vs NT$1.31 in 2Q 2022)Second quarter 2023 results: EPS: NT$1.86 (up from NT$1.31 in 2Q 2022). Revenue: NT$313.1m (up 73% from 2Q 2022). Net income: NT$199.5m (up 42% from 2Q 2022). Profit margin: 64% (down from 77% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Upcoming Dividend • Jul 20Upcoming dividend of NT$0.25 per share at 0.2% yieldEligible shareholders must have bought the stock before 27 July 2023. Payment date: 01 September 2023. Trailing yield: 0.2%. Lower than top quartile of Taiwanese dividend payers (5.5%). Lower than average of industry peers (1.4%).
お知らせ • Jul 06SCI Pharmtech, Inc. Announces Cash Dividend, Payable on September 1, 2023SCI Pharmtech, Inc. announced a cash dividend of TWD 23,845,593; TWD 0.25/per share. Ex-rights (ex-dividend) trading date is July 27, 2023. Ex-rights (ex-dividend) record date is August 2, 2023. The Payment date of cash dividend distribution is September 1, 2023.
Reported Earnings • Mar 24Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: NT$3.24 (up from NT$0.58 in FY 2021). Revenue: NT$899.7m (up 4.1% from FY 2021). Net income: NT$308.8m (up 454% from FY 2021). Profit margin: 34% (up from 6.4% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 49% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
Price Target Changed • Feb 01Price target increased by 24% to NT$104Up from NT$84.00, the current price target is an average from 2 analysts. New target price is 6.8% above last closing price of NT$97.40. Stock is up 18% over the past year. The company is forecast to post earnings per share of NT$2.70 for next year compared to NT$0.58 last year.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Wang Vincent was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Buying Opportunity • Nov 09Now 21% undervaluedOver the last 90 days, the stock is up 8.0%. The fair value is estimated to be NT$112, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 209% in 2 years. Earnings is forecast to grow by 243% in the next 2 years.
Major Estimate Revision • Aug 30Consensus revenue estimates fall by 25%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from NT$1.11b to NT$834.0m. EPS estimate fell from NT$4.90 to NT$2.53 per share. Net income forecast to grow 170% next year vs 49% growth forecast for Pharmaceuticals industry in Taiwan. Consensus price target up from NT$84.00 to NT$86.00. Share price rose 2.2% to NT$88.20 over the past week.
Reported Earnings • Aug 15Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: EPS: NT$1.47 (up from NT$0.039 in 2Q 2021). Revenue: NT$181.4m (up 2.7% from 2Q 2021). Net income: NT$140.3m (up NT$136.6m from 2Q 2021). Profit margin: 77% (up from 2.1% in 2Q 2021). The increase in margin was primarily driven by lower expenses. Revenue missed analyst estimates by 24%. Earnings per share (EPS) also missed analyst estimates by 63%. Over the next year, revenue is forecast to grow 134%, compared to a 27% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance.
お知らせ • Jun 30SCI Pharmtech, Inc. Announces Appointment of General Manager of the Board of DirectorsSCI Pharmtech, Inc. announced appointment of general manager of the Board of Directors. Name of the previous position holder: Mr. Weichyun Wong. Resume of the previous position holder: general manager of SCI Pharmtech, Inc. 5.Name of the new position holder: Mr. Wen-Chih Chou. Resume of the new position holder: Plant Manager of SCI Pharmtech, Inc. Effective date of the new appointment is June 29, 2022.
Reported Earnings • May 09First quarter 2022 earnings: EPS exceeds analyst expectationsFirst quarter 2022 results: EPS: NT$0.43 (down from NT$0.44 in 1Q 2021). Revenue: NT$188.0m (down 42% from 1Q 2021). Net income: NT$41.2m (down 1.2% from 1Q 2021). Profit margin: 22% (up from 13% in 1Q 2021). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Over the next year, revenue is forecast to grow 94%, compared to a 21% growth forecast for the industry in Taiwan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.
Price Target Changed • Apr 27Price target increased to NT$84.00Up from NT$66.94, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$82.00. Stock is up 7.9% over the past year. The company is forecast to post earnings per share of NT$4.90 for next year compared to NT$0.58 last year.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Jay Chen was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 07Third quarter 2021 earnings released: EPS NT$0.31 (vs NT$1.98 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$228.3m (down 66% from 3Q 2020). Net income: NT$29.9m (down 84% from 3Q 2020). Profit margin: 13% (down from 28% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
Upcoming Dividend • Aug 16Upcoming dividend of NT$0.50 per shareEligible shareholders must have bought the stock before 23 August 2021. Payment date: 28 September 2021. Trailing yield: 0.5%. Lower than top quartile of Taiwanese dividend payers (5.2%). Lower than average of industry peers (2.3%).
Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS NT$0.05 (vs NT$3.04 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$176.6m (down 76% from 2Q 2020). Net income: NT$3.75m (down 98% from 2Q 2020). Profit margin: 2.1% (down from 33% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Reported Earnings • May 08First quarter 2021 earnings released: EPS NT$0.52 (vs NT$2.62 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: NT$323.6m (down 59% from 1Q 2020). Net income: NT$41.7m (down 80% from 1Q 2020). Profit margin: 13% (down from 27% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 13% per year.
分析記事 • Apr 07Analysts Just Shipped A Captivating Upgrade To Their SCI Pharmtech, Inc. (TPE:4119) EstimatesSCI Pharmtech, Inc. ( TPE:4119 ) shareholders will have a reason to smile today, with the analysts making substantial...
Major Estimate Revision • Apr 07Consensus revenue estimates increase to NT$742.0mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from NT$609.0m to NT$742.0m. EPS estimate increased from NT$0.56 to NT$1.18 per share. Net income forecast to shrink 74% next year vs 10% growth forecast for Pharmaceuticals industry in Taiwan . Consensus price target up from NT$80.33 to NT$89.33. Share price was steady at NT$94.10 over the past week.
分析記事 • Mar 30There May Be Reason For Hope In SCI Pharmtech's (TPE:4119) Disappointing EarningsThe market for SCI Pharmtech, Inc.'s ( TPE:4119 ) shares didn't move much after it posted weak earnings recently. Our...
Reported Earnings • Mar 25Full year 2020 earnings released: EPS NT$4.53 (vs NT$7.19 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: NT$2.69b (up 14% from FY 2019). Net income: NT$360.1m (down 37% from FY 2019). Profit margin: 13% (down from 24% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
分析記事 • Mar 08SCI Pharmtech, Inc. (TPE:4119) Is Yielding 6.3% - But Is It A Buy?Today we'll take a closer look at SCI Pharmtech, Inc. ( TPE:4119 ) from a dividend investor's perspective. Owning a...
分析記事 • Jan 25SCI Pharmtech (TPE:4119) Shareholders Booked A 54% Gain In The Last Three YearsSCI Pharmtech, Inc. ( TPE:4119 ) shareholders might be concerned after seeing the share price drop 21% in the last...
Valuation Update With 7 Day Price Move • Jan 13Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$98.00, the stock is trading at a trailing P/E ratio of 10.7x, up from the previous P/E ratio of 9.1x. This compares to an average P/E of 18x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders over the past three years are 79%.
分析記事 • Dec 30Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's EstimatesMarket forces rained on the parade of SCI Pharmtech, Inc. ( TPE:4119 ) shareholders today, when the analysts downgraded...
Major Estimate Revision • Dec 30Analysts update estimatesThe 2020 consensus revenue estimate increased from NT$2.73b to NT$2.78b. Earnings per share (EPS) estimate was lowered from NT$9.58 to NT$5.75 for the same period. Net income is expected to shrink by 58% next year compared to 48% growth forecast for the Pharmaceuticals industry in Taiwan . The consensus price target was lowered from NT$109 to NT$85.67. Share price is down by 8.7% to NT$83.00 over the past week.
分析記事 • Dec 29Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?SCI Pharmtech (TPE:4119) has had a rough month with its share price down 36%. But if you pay close attention, you might...
Price Target Changed • Dec 22Price target lowered to NT$109Down from NT$131, the current price target is an average from 4 analysts. The new target price is 8.3% above the current share price of NT$101. As of last close, the stock is down 5.6% over the past year.
Valuation Update With 7 Day Price Move • Dec 22Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to NT$101, the stock is trading at a trailing P/E ratio of 11x, down from the previous P/E ratio of 13.6x. This compares to an average P/E of 19x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders over the past three years are 97%.
Is New 90 Day High Low • Dec 21New 90-day low: NT$112The company is down 8.0% from its price of NT$122 on 22 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is NT$139 per share.
分析記事 • Dec 08Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?Is SCI Pharmtech, Inc. ( TPE:4119 ) a good dividend stock? How can we tell? Dividend paying companies with growing...
分析記事 • Nov 17A Look At The Intrinsic Value Of SCI Pharmtech, Inc. (TPE:4119)In this article we are going to estimate the intrinsic value of SCI Pharmtech, Inc. (TPE:4119) by taking the expected...
Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS NT$2.38The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$678.8m (up 8.1% from 3Q 2019). Net income: NT$188.9m (up 18% from 3Q 2019). Profit margin: 28% (up from 26% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.
Analyst Estimate Surprise Post Earnings • Nov 15Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 0.05%. Earnings per share (EPS) missed analyst estimates by 2.1%. Over the next year, revenue is forecast to stay flat compared to a 79% growth forecast for the Pharmaceuticals industry in Taiwan.
Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS NT$2.38The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$678.8m (up 8.1% from 3Q 2019). Net income: NT$188.9m (up 18% from 3Q 2019). Profit margin: 28% (up from 26% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth.
Analyst Estimate Surprise Post Earnings • Nov 07Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 0.05%. Earnings per share (EPS) missed analyst estimates by 2.1%. Over the next year, revenue is forecast to stay flat compared to a 73% growth forecast for the Pharmaceuticals industry in Taiwan.
